Paramune

Paramune is a private, preclinical-stage biotech leveraging foundational discoveries from Stanford University to develop novel biologics for autoimmune diseases and cancer. Its approach focuses on identifying and targeting new disease mechanisms using advanced antibody formats. Led by a team of experienced physician-scientists and entrepreneurs, the company is building its pipeline with an aim for rapid progression into clinical development, operating from the San Francisco Bay Area.

Utilizes a flexible approach to next-generation biologic formats (monoclonal antibodies, bispecifics, engagers, antibody cocktails) to therapeutically engage novel molecular targets discovered through foundational immunology research.

Paramune operates in highly competitive spaces. In autoimmunity, it competes with large pharma and biotech companies developing biologic and small molecule therapies. In oncology, it faces competition from numerous firms advancing bispecifics, engagers, and other next-gen antibody therapies. Its differentiation hinges on the novelty of its targets and its translational research approach.